Alexandra Miller, MD, PhD
Neurologist & Neuro-Oncologist
My Role at MSKWe post reviews for MSK healthcare providers who have at least 30 patient experience surveys completed. If you do not see reviews for a provider, it may be because they do not yet have enough survey responses, or the provider may not be part of the group of healthcare providers included in the survey.
Only outpatient providers are included in the survey. Healthcare providers who only work in the hospital or in urgent care are not included in the survey. Pathologists or researchers who do not provide direct care to patients do not have reviews.
Areas of Expertise
My Specialties
- Primary Brain Tumors including Glioblastoma
- Anaplastic Glioma
- Low-grade Glioma
Request an Appointment
About Me
- Assistant Attending Physician
I am a neurologist who specializes in caring for people with gliomas, including glioblastoma and low-grade gliomas. I also have expertise in treating other primary central nervous system tumors, such as primary central nervous system lymphoma, ependymoma, and meningioma.
A neurologist is a doctor with special training in the brain, spinal cord, nerves, and muscles.
A neuro-oncologist is a doctor with special training in cancers that affect the brain, spinal cord, peripheral nerves, and muscles. This includes brain tumors and central nervous system tumors.
My Specialties
- Primary Brain Tumors including Glioblastoma
- Anaplastic Glioma
- Low-grade Glioma
- Ependymoma
- Meningioma
- and Central Nervous System Lymphoma
- Brain Metastases (Including Leptomeningeal Disease)
- Neurologic Complications of Cancer
Education
- MD, PhD, Yale University School of Medicine
Residencies
- Neurology – NewYork-Presbyterian/Weill Cornell Medical Center
Awards and Honors
- American Society of Clinical Oncology Young Investigator Award (2017)
Fellowships
- Neuro-Oncology – Memorial Sloan Kettering Cancer Center
Board Certifications
- Neurology
- Neuro-Oncology
Insurance Information
Understanding your insurance options is an important part of managing your cancer care. We have relationships with many common healthcare providers and plans.
In Network Coverage Type
PPO
In Network Coverage Type
HMO, PPO
In Network Coverage Type
HMO, EPO PPO, POS
In Network Coverage Type
PPO
In Network Coverage Type
EPO
In Network Coverage Type
EPO
In Network Coverage Type
Federal Government
In Network Coverage Type
PPO, POS, EPO, HMO
In Network Coverage Type
State Government
Don't see your carrier or plan? We can help you understand your coverage.
If you don't have health insurance or are worried that your care may not be fully covered, our financial assistance programs may be able to help.
If you have questions about insurance, call us at 646-497-9176.
Make an Appointment
New Patients
Current Patients
Contact and Location
Dr. Miller sees patients at three locations.
Looking to see a doctor at a different location? See all MSK locations.
Colleagues
Doctors at Memorial Sloan Kettering work as teams, with specialists from all different areas. This allows us to consider all your needs together, and to give you the best possible care.
Clinical Trials
Memorial Sloan Kettering's doctors and scientists are constantly developing new treatments for cancer. MSK is typically running hundreds of clinical trials at a given time.
You may be able to participate in a clinical trial even if you are new to MSK. Search our online directory to find trial information and see more about who can participate.
Search clinical trialsResearch and Publications
Tracking tumour evolution in glioma through liquid biopsies of cerebrospinal fluid. Miller AM, Shah RH, Pentsova EI, Pourmaleki M, Briggs S, Distefano N, Zheng Y, Skakodub A, Mehta SA, Campos C, Hsieh WY, Selcuklu SD, Ling L, Meng F, Jing X, Samoila A, Bale TA, Tsui DWY, Grommes C, Viale A, Souweidane MM, Tabar V, Brennan CW, Reiner AS, Rosenblum M, Panageas KS, DeAngelis LM, Young RJ, Berger MF, Mellinghoff IK. Nature. 2019 Jan 23; 565(7741):654-658.
Multiplexed immunofluorescence delineates proteomic cancer cell states associated with metabolism.Sood A, Miller AM, Brogi E, Sui Y, Armenia J, McDonough E, Santamaria-Pang A, Carlin S, Stamper A, Campos C, Pang Z, Li Q, Port E, Graeber TG, Schultz N, Ginty F, Larson SM, Mellinghoff IK. JCI Insight. 2016 May 5;1(6). pii: e87030.
An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells. Rohle D, Popovici-Muller J, Palaskas N, Turcan S, Grommes C, Campos C, Tsoi J, Clark O, Oldrini B, Komisopoulou E, Kunii K, Pedraza A, Schalm S, Silverman L, Miller A, Wang F, Yang H, Chen Y, Kernytsky A, Rosenblum MK, Liu W, Biller SA, Su SM, Brennan CW, Chan TA, Graeber TG, Yen KE, Mellinghoff IK. Science. 2013 May 3;340(6132):626-30. doi: 10.1126/science.1236062. Epub 2013 Apr 4.
Prognostic awareness, prognostic communication, and cognitive function in patients with malignant glioma. Diamond EL, Prigerson HG, Correa DC, Reiner A, Panageas K, Kryza-Lacombe M, Buthorn J, Neil EC, Miller AM, DeAngelis LM, Applebaum AJ. Neuro Oncol. 2017 Oct 19;19(11):1532-1541. doi: 10.1093/neuonc/nox117.
Patient Reviews
Your trust is our main concern
We strive to keep reviews trustworthy, honest and fair. Learn more about our patient experience reviews.
Disclosures
Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.
MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.
Alexandra Miller discloses the following relationships and financial interests:
No disclosures meeting criteria for time period
If you’re a patient at MSK and would like more information about your doctor’s external relationships, please talk with your doctor.
The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2022 through disclosure submission in spring 2023). This data reflects interests that may or may not still exist. This data is updated annually.
Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at [email protected].
